MiRNA-181家族与恶性肿瘤的研究进展  

Advances in research on miR-181 family members and malignant tumors

作　　者：朱耀魁[1] 程妮[1] 张磊[2] 岑颖洲[2] 

机构地区：[1]暨南大学附属第一医院妇产科,广东广州510632 [2]暨南大学生命学院化学系,广东广州5106322

出　　处：《肿瘤》2012年第10期837-841,共5页Tumor

基　　金：国家自然科学基金资助项目(编号:21310104);国家级创新创业基金资助项目(编号:50421250);广东省医学科学技术研究基金资助项目(编号:A2011344)

摘　　要：人类微RNA-181家族的成熟序列现有8个成员,拥有成千上万个预测靶标,其中只有少数靶标如骨桥蛋白(osteopontin,OPN)、Bcl-2、SHP2和K-ras基因等已被研究证实。MiRNA-181家族在肝癌、胃癌、口腔鳞状细胞癌、胶质瘤、肺癌、白血病、乳腺癌及食管癌等恶性肿瘤的发生和发展中扮演抑癌基因或促癌基因的重要角色,并与多种恶性肿瘤的耐药性、临床诊疗及预后密切相关。The mature sequences of hsa-miR-181 family contain 8 members and possess tens of thousands of predicted targets, some of which such as OPN （osteopontin）, Bcl-2, SHP2 and K-ras genes have been experimently comfirmed. The miR-181 family which is considered as tumor suppressor gene or oncogene has been demonstrated to play an important role in occurrence and progression of malignant tumors such as hepatocellular carcinoma, gastric cancer, oral squamous cell carcinoma, glioma, lung cancer, leukemia, breast cancer and esophageal cancer, and it is also closely associated with drug resistance, clinicopathological characteristics and prognosis of malignant tumors.

关 键 词：肿瘤 微RNA 基因调节 诊断 预后 人类微RNA-181 

分 类 号：R730.2[医药卫生—肿瘤]